Omeicos Therapeutics completed enrollment in the phase 2a PMD-OPTION study, evaluating OMT-28 in primary mitochondrial disease (PMD) patients with myopathy and cardiomyopathy.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.